BIIB vs. BMY
Compare and contrast key facts about Biogen Inc. (BIIB) and Bristol-Myers Squibb Company (BMY).
Performance
BIIB vs. BMY - Performance Comparison
Loading graphics...
BIIB vs. BMY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
BIIB Biogen Inc. | 4.17% | 15.09% | -40.91% | -6.55% | 15.42% | -2.02% | -17.48% | -1.39% | -5.54% | 12.34% |
BMY Bristol-Myers Squibb Company | 13.77% | 0.11% | 15.81% | -26.14% | 18.98% | 2.88% | 0.41% | 27.74% | -12.90% | 7.71% |
Fundamentals
BIIB:
$26.89B
BMY:
$123.79B
BIIB:
$8.82
BMY:
$3.46
BIIB:
20.77
BMY:
17.53
BIIB:
1.44
BMY:
1.00
BIIB:
2.74
BMY:
2.57
BIIB:
1.47
BMY:
2.22
BIIB:
$9.81B
BMY:
$48.19B
BIIB:
$6.91B
BMY:
$30.43B
BIIB:
$3.10B
BMY:
$13.82B
Returns By Period
In the year-to-date period, BIIB achieves a 4.17% return, which is significantly lower than BMY's 13.77% return. Over the past 10 years, BIIB has underperformed BMY with an annualized return of -3.45%, while BMY has yielded a comparatively higher 2.72% annualized return.
BIIB
- 1D
- -2.26%
- 1M
- -4.43%
- YTD
- 4.17%
- 6M
- 30.88%
- 1Y
- 33.97%
- 3Y*
- -12.96%
- 5Y*
- -8.04%
- 10Y*
- -3.45%
BMY
- 1D
- 1.54%
- 1M
- -2.76%
- YTD
- 13.77%
- 6M
- 37.94%
- 1Y
- 4.47%
- 3Y*
- 0.11%
- 5Y*
- 3.12%
- 10Y*
- 2.72%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BIIB vs. BMY — Risk / Return Rank
BIIB
BMY
BIIB vs. BMY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Biogen Inc. (BIIB) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| BIIB | BMY | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.99 | 0.16 | +0.83 |
Sortino ratioReturn per unit of downside risk | 1.63 | 0.43 | +1.21 |
Omega ratioGain probability vs. loss probability | 1.19 | 1.05 | +0.14 |
Calmar ratioReturn relative to maximum drawdown | 1.90 | 0.22 | +1.67 |
Martin ratioReturn relative to average drawdown | 4.80 | 0.35 | +4.45 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| BIIB | BMY | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.99 | 0.16 | +0.83 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.21 | 0.13 | -0.34 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.08 | 0.11 | -0.19 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.22 | 0.35 | -0.13 |
Correlation
The correlation between BIIB and BMY is 0.29, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
BIIB vs. BMY - Dividend Comparison
BIIB has not paid dividends to shareholders, while BMY's dividend yield for the trailing twelve months is around 4.11%.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BIIB Biogen Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
BMY Bristol-Myers Squibb Company | 4.11% | 4.60% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% |
Drawdowns
BIIB vs. BMY - Drawdown Comparison
The maximum BIIB drawdown since its inception was -89.98%, which is greater than BMY's maximum drawdown of -72.03%. Use the drawdown chart below to compare losses from any high point for BIIB and BMY.
Loading graphics...
Drawdown Indicators
| BIIB | BMY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -89.98% | -72.03% | -17.95% |
Max Drawdown (1Y)Largest decline over 1 year | -14.13% | -25.79% | +11.66% |
Max Drawdown (5Y)Largest decline over 5 years | -72.66% | -47.67% | -24.99% |
Max Drawdown (10Y)Largest decline over 10 years | -72.66% | -47.67% | -24.99% |
Current DrawdownCurrent decline from peak | -61.48% | -13.61% | -47.87% |
Average DrawdownAverage peak-to-trough decline | -36.48% | -22.40% | -14.08% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.78% | 17.63% | -10.85% |
Volatility
BIIB vs. BMY - Volatility Comparison
Biogen Inc. (BIIB) has a higher volatility of 8.91% compared to Bristol-Myers Squibb Company (BMY) at 6.67%. This indicates that BIIB's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| BIIB | BMY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.91% | 6.67% | +2.24% |
Volatility (6M)Calculated over the trailing 6-month period | 24.16% | 19.42% | +4.74% |
Volatility (1Y)Calculated over the trailing 1-year period | 34.48% | 28.60% | +5.88% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 38.11% | 23.66% | +14.45% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 41.40% | 25.08% | +16.32% |
Financials
BIIB vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Biogen Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
BIIB vs. BMY - Profitability Comparison
BIIB - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Biogen Inc. reported a gross profit of 1.78B and revenue of 2.28B. Therefore, the gross margin over that period was 78.2%.
BMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Bristol-Myers Squibb Company reported a gross profit of 6.24B and revenue of 12.50B. Therefore, the gross margin over that period was 49.9%.
BIIB - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Biogen Inc. reported an operating income of -57.00M and revenue of 2.28B, resulting in an operating margin of -2.5%.
BMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Bristol-Myers Squibb Company reported an operating income of 1.47B and revenue of 12.50B, resulting in an operating margin of 11.8%.
BIIB - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Biogen Inc. reported a net income of -48.41M and revenue of 2.28B, resulting in a net margin of -2.1%.
BMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Bristol-Myers Squibb Company reported a net income of 1.09B and revenue of 12.50B, resulting in a net margin of 8.7%.